These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21560638)

  • 1. [Biological therapy of inflammatory bowel disease].
    Lazebnik LB; Parfenov AI; Kniazev OV; Konopliannikov AG; Sagynbaeva VE; Iakovleva MV; Astrelina TA; Ruchkina IN; Shcherbakov PL; Trubitsyna IE; Tsaregorodtseva TM; Gudkova RB; Rogozina VA; Chikunova BZ; Khomeriki SG; Mikhaĭlova ZF
    Eksp Klin Gastroenterol; 2011; (2):7-14. PubMed ID: 21560638
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dynamics of proinflammatory cytokine in biological therapy of inflammatory bowel disease].
    Sagynbaeva VE; Lazebnik LB; Kniazev OV; Efremov LI
    Eksp Klin Gastroenterol; 2012; (2):76-87. PubMed ID: 22808797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological treatment of refractory Crohn's disease: three years of observation].
    Lazebnik LB; Kniazev OV; Parfenov AI; Konopliannikov AG; Sagynbaeva VE; Ruchkina IN; Gudkova RB; Khomeriki SG; Chikunova BZ; Mikhaĭlova ZF; Shcherbakov PL; Rogozina VA
    Eksp Klin Gastroenterol; 2011; (3):42-53. PubMed ID: 21695952
    [No Abstract]   [Full Text] [Related]  

  • 5. [Isolation of antibodies to Chlamydia and Mycoplasma pneumoniae during the immunosuppressive therapy of patients with inflammatory bowel disease].
    Sagynbaeva VE; Lazebnik LB; Kniazev OV; Parfenov AI; Efremov LI
    Eksp Klin Gastroenterol; 2012; (3):40-6. PubMed ID: 22830223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunobiology of chronic inflammatory bowel diseases].
    Siegmund B; Zeitz M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2657-60. PubMed ID: 17109275
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immune response to biological therapy of inflammatory bowel diseases].
    Kniazev OV; Parfenov AI; Ruchkina IN; Lazebnik LB; Sagynbaeva VÉ
    Ter Arkh; 2013; 85(12):55-9. PubMed ID: 24640669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The immune status changes in patients with inflammatory bowel disease under the influence of mesenchymal stromal cells and infliximab therapy].
    Lazebnik LB; Sagynbaeva VÉ; Knyazev OV; Parfenov AI; Efremov LI; Guseĭnzade MD; Ruchkina IN; Konopliannikov AG; Iakovleva MV; Astrelina TA
    Eksp Klin Gastroenterol; 2011; (9):11-7. PubMed ID: 22629769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological therapies of inflammatory bowel disease.
    Bai A; Peng Z
    Immunotherapy; 2010 Sep; 2(5):727-42. PubMed ID: 20874655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamics of proinflammatory cytokines during biologic therapy of inflammatory bowel disease].
    Sagynbaeva VE; Lazebnik LB; Kniazev OV; Efremov LI
    Eksp Klin Gastroenterol; 2012; (3):47-58. PubMed ID: 22830224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum calprotectin as a marker for determining the activity of the inflammatory process and the effectiveness of therapy in inflammatory bowel disease].
    Sagynbaeva VÉ; Lazebnik LB
    Eksp Klin Gastroenterol; 2014; (7):25-31. PubMed ID: 25842402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM; Schmidt D; Karlén P
    Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab.
    Barrie A; Plevy S
    Gastroenterol Clin North Am; 2006 Dec; 35(4):883-93. PubMed ID: 17129819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab safety profile and long-term applicability in inflammatory bowel disease: clinical experiences from the eastern side of Europe.
    Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T
    Aliment Pharmacol Ther; 2010 May; 31(10):1152-3. PubMed ID: 20518754
    [No Abstract]   [Full Text] [Related]  

  • 19. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 20. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.